Amgen 🧪🔬🧬

Amgen harnesses the best of biology and technology to fight the world’s toughest diseases.

🔗 Guidelines:

[Amgen 🧪🔬🧬 @Amgen]

A major milestone in our more than $1.5 billion investment in Holly Springs, North Carolina.

The final steel topping beam is now in place at Amgen’s newest advanced manufacturing facility — expanding U.S. biomanufacturing capabilities for the future.

$AMGN

[Amgen 🧪🔬🧬 @Amgen]

How will AI shape the future of Amgen?

CEO Bob Bradway recently joined Sarah Elk and AI pioneer @AndrewYNg on @BainandCompany's Winning with AI podcast to discuss how AI is helping accelerate innovation across drug discovery, development, and manufacturing.

🎙️Watch the full podcast: https://t.co/b74gV0ztBA

$AMGN

[Amgen 🧪🔬🧬 @Amgen]

📢 Amgen announced the presentation of new data across rare autoimmune & inflammatory diseases at #EULAR2026.

Research highlights IgG4-related disease & real-world evidence in ANCA-associated vasculitis.

🔗 Learn more: https://t.co/otHRorvV1S

$AMGN

[Amgen 🧪🔬🧬 @Amgen]

🔬 Small cell lung cancer news: Amgen’s DLL3-targeting therapy is now approved in the European Union for certain patients with extensive-stage small cell lung cancer (#SCLC).

🔗 Learn more: https://t.co/pmAchmc60u

[Amgen 🧪🔬🧬 @Amgen]

Cancer research doesn't stand still at Amgen.

At #ASCO2026, we’re sharing new data in SCLC, colorectal cancer, prostate cancer, Ewing sarcoma & more.

➡️ Explore full abstracts: https://t.co/2rHl2sPCbP

[Amgen 🧪🔬🧬 @Amgen]

Amgen announced the planned retirement of EVP and CFO Peter Griffith. Thomas Dittrich will return to Amgen and succeed Griffith as CFO effective Sept. 1, 2026.

“We are grateful to Peter for his leadership and lasting impact on the company,” said Chairman and CEO Robert A. Bradway.

More: https://t.co/3qjrG464Rx

$AMGN

[Amgen 🧪🔬🧬 @Amgen]

Headed to #ECO2026? Join us for our symposium and learn more about the evolving obesity treatment landscape.

🔗Learn more about our scientific approach to obesity: https://t.co/8L2JhqBblp

[Amgen 🧪🔬🧬 @Amgen]

@Tim46023972 Hello, we've sent you a DM. Thank you.

[Amgen 🧪🔬🧬 @Amgen]

@Tim46023972 Thank you for your message. We would like to contact you to learn more. Can you follow us back so we can send you a DM?

[Amgen 🧪🔬🧬 @Amgen]

@CatLady_Anne Thank you for your message. We would like to contact you to learn more. Can you follow us back so we can send you a DM?

[Amgen 🧪🔬🧬 @Amgen]

Amgen is investing an additional $300M in its U.S. manufacturing network to advance production capacity, enhance next-generation technologies and support a reliable supply of medicines.

Total U.S. manufacturing investments announced over the past year now reach nearly $2B.

🔗See how Amgen is leading what’s next in biotech innovation: https://t.co/wy73w6TDki

$AMGN

[Amgen 🧪🔬🧬 @Amgen]

How do you navigate B-cell ALL at 21?

After years of hospital stays & uncertainty, William is in remission. Now he’s helping other young people advocate for themselves.

Read his story: https://t.co/s99Dzgftsq @TheMightySite

#AmgenSponsored

[Jenniffer González @Jenniffer]

AMGEN continúa fortaleciendo su presencia en nuestra isla con una inversión adicional de $300 millones, impulsando la creación de empleos, el desarrollo económico y nuevas oportunidades para nuestra gente.

Por más de tres décadas, esta alianza ha sido parte clave del crecimiento industrial y científico de Puerto Rico, demostrando la confianza de empresas globales en el talento puertorriqueño y en el potencial de nuestra isla.

[Amgen 🧪🔬🧬 @Amgen]

Amgen reports Q1 2026 earnings: https://t.co/MEqJyAR3r0

Safe Harbor: https://t.co/0qOJUqZrLu

$AMGN

[Amgen 🧪🔬🧬 @Amgen]

Amgen will report Q1 2026 financial results tomorrow.

Details here: https://t.co/MC13amBIj7

$AMGN

[Amgen 🧪🔬🧬 @Amgen]

Amgen will report Q1 2026 financial results on Thursday, April 30.

Details here: https://t.co/02N9Ypn5yR

$AMGN

[Amgen 🧪🔬🧬 @Amgen]

🔬Amgen San Francisco has expanded with new small-molecule discovery labs.

Powered by the DMTA cycle: Design → Make → Test → Analyze

Scientists are working to accelerate discovery, designing molecules that could one day become medicines. 🎉

[Amgen 🧪🔬🧬 @Amgen]

We’re excited to share positive Phase 3 data evaluating a subcutaneous administration of our treatment for Thyroid Eye Disease (TED) in people with moderate-to-severe active TED.

🔗 Read the press release to learn more: https://t.co/fCDreCselb

$AMGN

[Amgen 🧪🔬🧬 @Amgen]

@Tim46023972 We've just followed you. Can you follow us back so we can learn more. Thank you.

[Amgen 🧪🔬🧬 @Amgen]

Amgen has published its 2025 Letter to Shareholders. 🔗https://t.co/kafOkl4pQE

This year’s letter highlights our strong performance in 2025 and how we are advancing innovative medicines, driving scientific innovation, and investing in manufacturing to better serve patients around the world.

$AMGN